You are here: Industry Insights > sclerosis

News List

Obesity May Boost Odds for MS in Kids drugs
July 17, 2019
Obese children may be twice as likely to develop multiple sclerosis, a new study suggests.
Obesity Linked to Increased Risk for Pediatric Multiple Sclerosis drugs
July 16, 2019
Obesity seems to be associated with increased odds of pediatric multiple sclerosis (MS), according to a study published online in JAMA Neurology.
Standing Frame Program Can Up Motor Function in Progressive MS drugs
July 15, 2019
Standing Frame Program Can Up Motor Function in Progressive MS.
US FDA and EMA Accept Applications for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis drugs
June 11, 2019
US FDA and EMA Accept Applications for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis.
Recommendations Developed for Pediatric Multiple Sclerosis Trials drugs
June 03, 2019
Recommendations Developed for Pediatric Multiple Sclerosis Trials.
3F4AP tracer can measure demyelination in multiple sclerosis europeanpharmaceuticalreview
April 30, 2019
PET imaging may improve diagnosis and monitoring for MS patients…
Ocrelizumab reccommended for relapsing remitting multiple sclerosis europeanpharmaceuticalreview
April 16, 2019
Ocrelizumab has been recommended by the Scottish Medicines Consortium to treat relapsing remitting multiple sclerosis (RRMS) in adults...
Celgene Submits Application to FDA for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis drugs
April 11, 2019
Celgene Submits Application to FDA for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis.
Boehringer Ingelheim announces FDA and EMA regulatory submission for nintedanib in systemic sclerosis associated ILD worldpharmanews
March 27, 2019
Boehringer Ingelheim has filed for regulatory approval of nintedanib in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD) with the FDA and EMA.
Sanofi, Principia Agree To Develop Multiple Sclerosis Drug Candidate americanpharmaceuticacreview
November 10, 2017
Sanofi will develop Principia Biopharma experimental oral treatment that shows promise in multiple sclerosis (MS) and, potentially, other central nervous system (CNS) diseases.

Previous page 1 2 3 Next page